

SENTARA COMMUNITY PLAN (MEDICAID)

MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-844-305-2331. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If information provided is not complete, correct, or legible, authorization can be delayed.

Drug Requested: Oxlumio[®] (lumasiran) J0224 (MEDICAL)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight: _____ Date: _____

- ☐ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

Recommended Dosage:

- Loading dose: 3 mg/kg/dose once monthly for 3 doses. Maintenance dose: 3 mg/kg/dose every 3 months, beginning 1 month after last loading dose
- Oxlumio 94.5 mg/0.5 mL single-dose vial for injection: 4 vials every month for 3 doses then every 3 months thereafter

Max Units (per dose and over time) [HCPS Unit]:

- 345 mg every month for 3 doses then every 3 months thereafter; 1 vial (94.5 mg/0.5 mL) = 189 billable units

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Initial Authorization: 6 months

- ☐ Must be prescribed by a Geneticist, Nephrologist or Urologist with expertise in the diagnosis and treatment of primary hyperoxaluria type 1 (PH1)
- ☐ Member has a definitive diagnosis of PH1 confirmed by **ONE** of the following (**must submit documentation**):
 - ☐ Member has a biallelic pathogenic mutation in the alanine:glyoxylate aminotransferase (AGXT) gene as identified on molecular genetic testing
 - ☐ Identification of alanine:glyoxylate aminotransferase (AGT) enzyme deficiency on liver biopsy
- ☐ Member has signs and symptoms of PH1 (e.g., recurrent kidney stones, urolithiasis, infantile oxalosis, failure to thrive and renal failure, nephrocalcinosis associated with decreased GFR, oxalate crystals in any biological fluid or tissue, increased serum creatinine with calcium oxylate (CaOx) stones, CaOx tissue deposits, renal failure of unknown causes)
- ☐ Member has **ONE** of the following (**must submit lab documentation**):
 - ☐ Increased urinary oxalate excretion (i.e. greater than 0.7 mmol/1.73 m² per day [90 mg/1.73 m² per day])
 - ☐ Increased urinary oxalate:creatinine ratio relative to normative values for age
- ☐ Member does **NOT** have severe kidney damage (eGFR <30 mL/min/1.73 m²), is **NOT** receiving hemodialysis and has **NOT** previously received a liver or kidney transplant
- ☐ Provider has submitted labs documenting member's current 24-hour urinary oxalate excretion (corrected for BSA) _____
- ☐ Provider has submitted member's baseline plasma oxylate levels _____
- ☐ Member does **NOT** have secondary causes of hyperoxaluria (e.g., diet with excessive intake of oxylate, gastric bypass surgery, Irritable Bowel Disease, other intestinal disorders, etc.)
- ☐ Requested dosing is in accordance with the United States Food and Drug Administration approved labeling

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ☐ Provider has submitted medical records (i.e., chart notes, laboratory values) documenting a positive clinical response to therapy from pre-treatment baseline (i.e., decreased urinary oxalate concentrations, decreased urinary oxalate:creatinine ratio, decreased plasma oxalate concentrations)
- ☐ Member does **NOT** have severe kidney damage (eGFR <30 mL/min/1.73 m²), is **NOT** receiving hemodialysis and has **NOT** received a liver or kidney transplant

(Continued on next page)

Medication being provided by: Please check applicable box below.

☐ Physician's office OR ☐ Specialty Pharmacy – PropriumRx

For urgent reviews: Practitioner should call Sentara Health Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. Sentara Health's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****